New studies have uncovered how immunotherapies targeting the immune checkpoints PD1 and LAG3 work in concert to active immune responses and may improve outcomes in patients with melanoma compared with monotherapies targeting only PD1.
Health Professionals
Dr Tarhini on Hogh-Dose Bolus IL-2 With Ipilimumab Followed by Nivolumab in Melanoma
Ahmad Tarhini, MD, PhD, director, Cutaneous Clinical and Translational Research, leader, Neoadjuvant and Adjuvant Translational Science Program, senior member, Moffitt Cancer Center, Research Institute Departments of Cutaneous Oncology and Immunology; professor, Oncologic Sciences, University of South Florida Morsani College of Medicine; chair, Scientific Committee, Oncology Research Information Exchange Network (ORIEN); chair, ORIEN ImmunoOncology Research Subcommittee, discusses the use of high-dose bolus interleukin-2 (IL-2) with concurrent low-dose ipilimumab (Yervoy), followed sequentially by nivolumab (Opdivo), in patients with advanced melanoma.
15-year-old Virginia scientist created a soap that could treat skin cancer, named Time’s 2024 Kid of the Year
Time magazine and Time for Kids has chosen its 2024 Kid of the Year — and it’s Heman Bekele, a teenager who could change the way skin cancer is treated.
Innovative Melanoma Treatment Among NCInnovation’s $5.2 Million Research Funding Recipients
Michelle Bolas and Rukiyah T. Van Dross-Anderson, PhD, discuss the significance of NCInnovations’ funding and the clinical impact of Van Dross-Anderson’s research in patients with advanced melanoma.